КАРДИАЛЬНЫЕ НАРУШЕНИЯ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ ИММУНОВОСПАЛИТЕЛЬНЫЕ МЕХАНИЗМЫ И ВОЗМОЖНОСТИ РАННЕЙ ДИАГНОСТИКИ
- Авторы:Мирахмедова Хилола Тухтасиновна , Мирзалиева Анора Аргинбаевна
- Дата публикации:November 19, 2026
- Тип:Статья
- DOI: 10.64156/mju.10003 Скопировано
- Том / № Выпуска:Том 1 №6 (2026)
Аннотация
Аннотация. Рассмотрены механизмы поражения сердца при системной красной волчанке, роль воспалительных и кардиальных биомаркеров, возможности инструментальной диагностики и ограничения комплексной оценки.
Ключевые слова: системная красная волчанка; кардиальное поражение; субклиническая дисфункция миокарда; интерлейкин-1β; интерлейкин-6; параоксоназа-1; натрийуретические пептиды; электрокардиография; эхокардиография.
Annotatsiya. Tizimli qizil bo‘richada yurak shikastlanishi mexanizmlari, yallig‘lanish va kardial biomarkerlar, instrumental tashxislash imkoniyatlari hamda kompleks baholash cheklovlari ko‘rib chiqilgan.
Kalit so‘zlar: tizimli qizil bo‘richa; kardial shikastlanish; subklinik miokard disfunksiyasi; interleykin-1β; interleykin-6; paraoksonaza-1; natriyuretik peptidlar; elektrokardiografiya; exokardiografiya.
Abstract. This review examines cardiac involvement in systemic lupus erythematosus, inflammatory and cardiac biomarkers, instrumental diagnostic methods, and limitations of integrated assessment.
Keywords: systemic lupus erythematosus; cardiac involvement; subclinical myocardial dysfunction; interleukin-1β; interleukin-6; paraoxonase-1; natriuretic peptides; electrocardiography; echocardiography.
References
- Batuca J.R., Ames P.R.J., Amaral M., Favas C., Isenberg D.A., Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus // Rheumatology. 2009. Vol. 48, № 1. P. 26–31. doi:10.1093/rheumatology/ken397.
- Bello N., Meyers K.J., Workman J., Hartley L., McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis // Lupus. 2023. Vol. 32, № 3. P. 325–341. doi:10.1177/09612033221147471.
- Chung C.P., Solus J.F., Oeser A. et al. N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification // The Journal of Rheumatology. 2008. Vol. 35, № 7. P. 1314–1319.
- Ding J., Su S., You T. et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis // Clinics. 2020. Vol. 75. Article e1801. doi:10.6061/clinics/2020/e1801.
- Drosos G.C., Vedder D., Houben E. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome // Annals of the Rheumatic Diseases. 2022. Vol. 81, № 6. P. 768–779. doi:10.1136/annrheumdis-2021-221733.
- Gaál K., Tarr T., Lőrincz H. et al. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus // Lipids in Health and Disease. 2016. Vol. 15. Article 60. doi:10.1186/s12944-016-0229-0.
- Kadoglou N.P.E., Dimopoulou A., Korakianitis I., Parperis K. Advanced Parameters of Myocardial Strain and Cardiac Biomarkers Indicate Subclinical Systolic Myocardial Dysfunction in Patients with Systemic Lupus Erythematous // Biomedicines. 2024. Vol. 12, № 11. Article 2638. doi:10.3390/biomedicines12112638.
- Kiss E., Seres I., Tarr T., Kocsis Z., Szegedi G., Paragh G. Reduced Paraoxonase1 Activity Is a Risk for Atherosclerosis in Patients with Systemic Lupus Erythematosus // Annals of the New York Academy of Sciences. 2007. Vol. 1108, № 1. P. 83–91. doi:10.1196/annals.1422.009.
- Mackness M., Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles // Gene. 2015. Vol. 567, № 1. P. 12–21. doi:10.1016/j.gene.2015.04.088.
- Moyssakis I., Tektonidou M.G., Vasilliou V.A. et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution // The American Journal of Medicine. 2007. Vol. 120, № 7. P. 636–642. doi:10.1016/j.amjmed.2007.01.024.
- Nagueh S.F., Smiseth O.A., Appleton C.P. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // Journal of the American Society of Echocardiography. 2016. Vol. 29, № 4. P. 277–314. doi:10.1016/j.echo.2016.01.011.
- Nagueh S.F., Sanborn D.Y., Oh J.K. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography // Journal of the American Society of Echocardiography. 2025. Vol. 38, № 7. P. 537–569. doi:10.1016/j.echo.2025.03.011.
- Nikolic R.P.A., Virk M.K., Buhler K.A. et al. Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis // Journal of Cardiovascular Pharmacology. 2024. Vol. 84, № 2. P. 158–169. doi:10.1097/FJC.0000000000001589.
- Oliveira C.B., Kaplan M.J. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus // Seminars in Immunopathology. 2022. Vol. 44, № 3. P. 309–324. doi:10.1007/s00281-022-00922-y.
- Pędzich E., Bednarek A., Młynarska J. et al. An update on cardiovascular disorders in systemic lupus erythematosus // Advances in Clinical and Experimental Medicine. 2025. Vol. 34, № 2. P. 269–281. doi:10.17219/acem/184868.
- Sacre K., Vinet E., Pineau C.A. et al. N-terminal pro-brain natriuretic peptide is a biomarker for cardiovascular damage in systemic lupus erythematous: a cross-sectional study // Rheumatology. 2024. Vol. 63, № 6. P. 1739–1745. doi:10.1093/rheumatology/kead522.
- Tian J., Zhang D., Yao X., Huang Y., Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study // Annals of the Rheumatic Diseases. 2023. Vol. 82, № 3. P. 351–356. doi:10.1136/ard-2022-223035.
- Tsokos G.C. The immunology of systemic lupus erythematosus // Nature Immunology. 2024. Vol. 25, № 8. P. 1332–1343. doi:10.1038/s41590-024-01898-7.
- . Tsutsui H., Albert N.M., Coats A.J.S. et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society // European Journal of Heart Failure. 2023. Vol. 25, № 5. P. 616–631. doi:10.1002/ejhf.2848.
- Wei J., Wang A., Li B. et al. Pathological mechanisms and crosstalk among various cell death pathways in cardiac involvement of systemic lupus erythematosus // Frontiers in Immunology. 2024. Vol. 15. Article 1452678. doi:10.3389/fimmu.2024.1452678.